Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344472 | 0.87 | NR1H2 (0.41) | NR1H2NAMPTACKR3GLSGPR119 | |
| SCHEMBL23802316 | 0.72 | NR1H2 (0.44) | NR1H2NAMPTGPR119USP7 | |
| SCHEMBL19521310 | 0.71 | NAMPT (0.46) | NR1H2NAMPTKDM4ERORC | |
| SCHEMBL23802315 | 0.70 | NR1H2 (0.44) | NR1H2NAMPTGPR119KDM4E | |
| SCHEMBL16098021 | 0.70 | NR1H2 (0.49) | NR1H2NAMPTGPR119KDM4EPKM | |
| SCHEMBL3001141 | 0.69 | NR1H2 (0.58) | NR1H2NAMPTKDM4EPKMRORC | |
| SCHEMBL29206705 | 0.68 | NR1H2 (0.50) | NR1H2NAMPTGPR119KDM4E | |
| SCHEMBL3450016 | 0.68 | KDM4E (0.46) | GPR119KDM4EPKMUSP7 | |
| SCHEMBL31108119 | 0.68 | USP30 (0.43) | NR1H2NAMPTKDM4ERORC | |
| SCHEMBL447929 | 0.67 | NR1H2 (0.60) | NR1H2NAMPTKDM4EPKMRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | NR1H2 107/4885NAMPT 3148/4885ACKR3 526/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | NR1H2 107/4885NAMPT 3148/4885ACKR3 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.